Watch ZNTL. Know when insiders buy.
One email the day a filing lands. Free.
ZNTL
Zentalis Pharmaceuticals, Inc.
2.52
−0.09 −3.26%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
99
PASS · shorts 99
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $180.6MP/E —DIV YIELD —FCF YIELD -70.94%REV TTM —NET INCOME −$139.5MNET CASH —52W 1.28 – 6.61SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$44.4M | −$42.3M | — | -0.59 | −$37.2M | $0 | −$37.2M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$37.9M | −$35.4M | — | -0.50 | −$33M | $34K | −$33M | May 12 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$37.4M | −$35.2M | — | -0.49 | −$30.9M | $0 | −$30.9M | Mar 26 |
| Q3 2025 · Sep 30 | $0 | — | — | −$33.7M | −$26.7M | — | -0.37 | −$27M | $0 | −$27M | Nov 10 |
| Q2 2025 · Jun 30 | $0 | — | — | −$36.1M | −$26.9M | — | -0.37 | −$34.7M | $0 | −$34.7M | Aug 6 |
| Q1 2025 · Mar 31 | $0 | −100.0% | — | −$45.6M | −$48.3M | −579.5% | -0.67 | −$32.6M | $0 | −$32.6M | May 12 |
| Q4 2024 · Dec 31derived | $26.9M | — | — | −$49.8M | −$47.5M | — | -0.66 | −$39.7M | $0 | −$39.7M | Mar 26 |
| Q3 2024 · Sep 30 | $0 | — | — | −$51.4M | −$40.2M | — | -0.56 | −$44M | $0 | −$44M | Nov 10 |
| Q2 2024 · Jun 30 | $0 | — | — | −$65.1M | −$88.3M | — | -1.24 | −$35.1M | $181K | −$35.3M | Aug 6 |
| Q1 2024 · Mar 31 | $40.6M | — | — | −$24.8M | $10.1M | — | 0.14 | −$52M | $40K | −$52M | May 14 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$67.9M | −$60.9M | — | -0.83 | −$40.6M | $173K | −$40.8M | Mar 26 |
| Q3 2023 · Sep 30 | $0 | — | — | −$62.7M | −$55.5M | — | -0.79 | −$38.7M | $91K | −$38.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$152.8M | −$137.1M | — | -1.91 | −$125.2M | $0 | −$125.2M | $10M | — |
| FY2024 · to Dec 31 | $67.4M | — | −$191.2M | −$165.8M | -246.0% | -2.33 | −$170.9M | $221K | −$171.1M | $0 | — |
| FY2023 · to Dec 31 | $0 | — | −$299.5M | −$292.2M | — | -4.47 | −$207.8M | $583K | −$208.4M | $0 | — |
| FY2022 · to Dec 31 | $0 | — | −$227.3M | −$236.8M | — | -4.48 | −$163.8M | $2.5M | −$166.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$216.5M | −$158.7M | — | -3.72 | −$154.1M | $6.1M | −$160.2M | — | — |
| FY2020 · to Dec 31 | — | — | −$118.8M | −$117.8M | — | -4.19 | −$86.8M | $758K | −$87.6M | — | — |
Every number comes from Zentalis Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.